GSK seeks to boost oncology repertoire with $5.1bn acquisition

03-12-2018

GSK seeks to boost oncology repertoire with $5.1bn acquisition

designer491 / iStockphoto.com

GSK has agreed to buy US oncology company Tesaro for $5.1 billion (£4 billion), in a move designed to strengthen its anti-cancer offering.


GSK, Tesaro, oncology, Zejula, BRCA, cancer, Emma Walmsley

LSIPR